Our Work in Neurology
Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the multiple sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category as the increased risk tolerance and the expanding number of therapies evolves the treatment strategies for all forms of MS.
Multiple Sclerosis, Rare Neurological Diseases
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.
With Ocrevus Uptake in Primary Progressive Multiple Sclerosis a Relative Lock, Genentech and US Neurologists are Increasingly Focused on Ocrevus Positioning in Relapsing Forms of Multiple Sclerosis – December 7, 2017
Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA’s Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosisk – November 21, 2017
Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody Disease-Modifying Therapies Compared to Neurologists in the US – November 15, 2017
FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa – October 4, 2017